Whole-genome landscapes of major melanoma subtypes

Nature

Volumn 545, Issue 7653, 2017, Pages 175-180

  Hayward, Nicholas K ^a,b   Wilmott, James S ^a,c   Waddell, Nicola ^b,d   Johansson, Peter A ^b   Field, Matthew A ^e   Nones, Katia ^b,d   Patch, Ann Marie ^b,d   Kakavand, Hojabr ^c   Alexandrov, Ludmil B ^f   Burke, Hazel ^a   Jakrot, Valerie ^a   Kazakoff, Stephen ^b,d   Holmes, Oliver ^b,d   Leonard, Conrad ^b,d   Sabarinathan, Radhakrishnan ^g,h   Mularoni, Loris ^g,h   Wood, Scott ^b,d   Xu, Qinying ^b,d   Waddell, Nick ^d   Tembe, Varsha ^a   Pupo, Gulietta M ^a   De Paoli Iseppi, Ricardo ^c   Vilain, Ricardo E ^c   Shang, Ping ^c   Lau, Loretta M S ^a   Dagg, Rebecca A ^a   Schramm, Sarah Jane ^a   Pritchard, Antonia ^b   Dutton Regester, Ken ^b   Newell, Felicity ^b   Fitzgerald, Anna ⁱ   Shang, Catherine A ⁱ   Grimmond, Sean M ^j   Pickett, Hilda A ^a   Yang, Jean Y ^a   Stretch, Jonathan R ^a   Behren, Andreas ^k   Kefford, Richard F ^a,l   Hersey, Peter ^a   Long, Georgina V ^a,m   Cebon, Jonathan ^k   Shackleton, Mark ⁿ   Spillane, Andrew J ^a   Saw, Robyn P M ^a   López Bigas, Núria ^g,h,o   Pearson, John V ^b,d   Thompson, John F ^a   Scolyer, Richard A ^a,c,p   Mann, Graham J ^a   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e JAMES COOK UNIVERSITY   (Australia)

^f LOS ALAMOS NATIONAL LABORATORY   (United States)

^g UNIVERSITAT POMPEU FABRA   (Spain)

^h INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

ⁱ Bioplatforms Australia Ltd   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^l MACQUARIE UNIVERSITY   (Australia)

^m ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁿ PETER MACCALLUM CANCER CENTRE   (Australia)

^o INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^p ROYAL PRINCE ALFRED HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR I; P21 ACTIVATED KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; ATRX PROTEIN, HUMAN; BRAF PROTEIN, HUMAN; DNA HELICASE; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; RNA SPLICING FACTOR; SF3B1 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

CANCER; ENZYME ACTIVITY; GENETIC ANALYSIS; GENOME; MUTATION; PROTEIN; SKIN DISORDER; ULTRAVIOLET RADIATION;

ARTICLE; ATRX GENE; CHROMOSOME 4; CUTANEOUS MELANOMA; GENE; GENE FUSION; HUMAN; HUMAN TISSUE; MELANOMA; MUCOSAL MELANOMA; ONCOGENE N RAS; PRIORITY JOURNAL; TELOMERE LENGTH; ULTRAVIOLET RADIATION; WHOLE GENOME SEQUENCING; ADVERSE EFFECTS; CLASSIFICATION; DRUG EFFECTS; GENETICS; HUMAN GENOME; MUTATION; NEUROFIBROMATOSIS TYPE 1; SIGNAL TRANSDUCTION; TELOMERE; TUMOR SUPPRESSOR GENE;

DNA HELICASES; GENES, P16; GENOME, HUMAN; GTP PHOSPHOHYDROLASES; HUMANS; MELANOMA; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEUROFIBROMATOSIS 1; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RNA SPLICING FACTORS; SIGNAL TRANSDUCTION; TELOMERASE; TELOMERE; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 85019207093     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22071     Document Type: Article

References (54)

1. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
2. Cancer Genome Atlas Network. Genomic classifcation of cutaneous melanoma. Cell 161, 1681-1696 (2015).
3. Krauthammer, M. et al. Exome sequencing identifes recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014 (2012).
4. Berger, M. F. et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506 (2012).
5. Chi, Z. et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11, 85 (2011).
6. Furney, S. J. et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J. Pathol. 230, 261-269 (2013).
7. Furney, S. J. et al. The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res. 27, 835-838 (2014).
8. Ravanat, J. L., Douki, T. & Cadet, J. Direct and indirect efects of UV radiation on DNA and its components. J. Photochem. Photobiol. B 63, 88-102 (2001).
9. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Reports 3, 246-259 (2013).
10. Alexandrov, L. B. & Stratton, M. R. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr. Opin. Genet. Dev. 24, 52-60 (2014).
11. Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015-1016 (2014).
12. Mardin, B. R. et al. A cell-based model system links chromothripsis with hyperploidy. Mol. Syst. Biol. 11, 828 (2015).
13. Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).
14. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959-961 (2013).
15. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959 (2013).
16. Bell, R. J. et al. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348, 1036-1039 (2015).
17. Liau, J. Y. et al. TERT promoter mutation is uncommon in acral lentiginous melanoma. J. Cutan. Pathol. 41, 504-508 (2014).
18. Fredriksson, N. J., Ny, L., Nilsson, J. A. & Larsson, E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat. Genet. 46, 1258-1263 (2014).
19. Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A. & Reddel, R. R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 3, 1271-1274 (1997).
20. Ramamoorthy, M. & Smith, S. Loss of ATRX suppresses resolution of telomere cohesion to control recombination in ALT cancer cells. Cancer Cell 28, 357-369 (2015).
21. Wiestler, B. et al. ATRX loss refnes the classifcation of anaplastic gliomas and identifes a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 126, 443-451 (2013).
22. Mularoni, L., Sabarinathan, R., Deu-Pons, J., Gonzalez-Perez, A. & López-Bigas, N. OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations. Genome Biol. 17, 128 (2016).
23. Sabarinathan, R., Mularoni, L., Deu-Pons, J., Gonzalez-Perez, A. & López-Bigas, N. Nucleotide excision repair is impaired by binding of transcription factors to DNA. Nature 532, 264-267 (2016).
24. Shain, A. H. et al. Exome sequencing of desmoplastic melanoma identifes recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat. Genet. 47, 1194-1199 (2015).
25. Dutton-Regester, K. et al. A highly recurrent RPS27 5′ UTR mutation in melanoma. Oncotarget 5, 2912-2917 (2014).
26. Ding, L. et al. Clonal architectures and driver mutations in metastatic melanomas. PLoS ONE 9, e111153 (2014).
27. Andersen, L. B. et al. Mutations in the neurofbromatosis 1 gene in sporadic malignant melanoma cell lines. Nat. Genet. 3, 118-121 (1993).
28. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
29. Krauthammer, M. et al. Exome sequencing identifes recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat. Genet. 47, 996-1002 (2015).
30. Stark, M. S. et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identifed by exome sequencing. Nat. Genet. 44, 165-169 (2011).
31. Curtin, J. A., Busam, K., Pinkel, D. & Bastian, B. C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346 (2006).
32. Arafeh, R. et al. Recurrent inactivating RASA2 mutations in melanoma. Nature Genet. 47, 1408-1410 (2015).
33. Harbour, J. W. et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45, 133-135 (2013).
34. Van Raamsdonk, C. D. et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602 (2009).
35. Palanisamy, N. et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16, 793-798 (2010).
36. Nikolaev, S. I. et al. Exome sequencing identifes recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44, 133-139 (2011).
37. Prickett, T. D. et al. Exon capture analysis of G protein-coupled receptors identifes activating mutations in GRM3 in melanoma. Nat. Genet. 43, 1119-1126 (2011).
38. Wei, X. et al. Exome sequencing identifes GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446 (2011).
39. Jones, D. T. et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28, 2119-2123 (2009).
40. Dutton-Regester, K. et al. Melanomas of unknown primary have a mutation profle consistent with cutaneous sun-exposed melanoma. Pigment Cell Melanoma Res. 26, 852-860 (2013).
41. Kassahn, K. S. et al. Somatic point mutation calling in low cellularity tumors. PLoS ONE 8, e74380 (2013).
42. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
43. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865-2871 (2009).
44. Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993-998 (2010).
45. Ha, G. et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. 24, 1881-1893 (2014).
46. Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489-494 (2015).
47. Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226-1236 (2013).
48. Kinsella, M. & Bafna, V. Combinatorics of the breakage-fusion-bridge mechanism. J. Computat. Biol. 19, 662-678 (2012).
49. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310-315 (2014).
50. Fu, Y. et al. FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer. Genome Biol. 15, 480 (2014).
51. Lau, L. M. et al. Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Res. 41, e34 (2013).
52. Griewank, K. G. et al. TERT promoter mutations are frequent in atypical fbroxanthomas and pleomorphic dermal sarcomas. Mod. Pathol. 27, 502-508 (2014).
53. Li, B. & Dewey, C. N. RSEM: accurate transcript quantifcation from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
54. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382-396 (2015).